Terns Pharmaceuticals Statistics
Total Valuation
TERN has a market cap or net worth of $340.18 million. The enterprise value is -$31.29 million.
Important Dates
The next estimated earnings date is Thursday, March 13, 2025, after market close.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TERN has 84.94 million shares outstanding. The number of shares has increased by 11.75% in one year.
| Current Share Class | 84.94M |
| Shares Outstanding | 84.94M |
| Shares Change (YoY) | +11.75% |
| Shares Change (QoQ) | +4.51% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 62.29% |
| Float | 51.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.99, with a Debt / Equity ratio of 0.00.
| Current Ratio | 32.99 |
| Quick Ratio | 32.67 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.28% and return on invested capital (ROIC) is -20.00%.
| Return on Equity (ROE) | -28.28% |
| Return on Assets (ROA) | -19.23% |
| Return on Invested Capital (ROIC) | -20.00% |
| Return on Capital Employed (ROCE) | -27.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 66 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TERN has paid $269,000 in taxes.
| Income Tax | 269,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.39% in the last 52 weeks. The beta is -0.36, so TERN's price volatility has been lower than the market average.
| Beta (5Y) | -0.36 |
| 52-Week Price Change | -46.39% |
| 50-Day Moving Average | 5.13 |
| 200-Day Moving Average | 6.84 |
| Relative Strength Index (RSI) | 33.74 |
| Average Volume (20 Days) | 1,725,096 |
Short Selling Information
The latest short interest is 6.45 million, so 7.60% of the outstanding shares have been sold short.
| Short Interest | 6.45M |
| Short Previous Month | 7.64M |
| Short % of Shares Out | 7.60% |
| Short % of Float | 12.57% |
| Short Ratio (days to cover) | 3.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -99.98M |
| Pretax Income | -95.63M |
| Net Income | -88.07M |
| EBITDA | -99.66M |
| EBIT | -99.98M |
| Earnings Per Share (EPS) | -$1.18 |
Full Income StatementBalance Sheet
The company has $372.78 million in cash and $1.31 million in debt, giving a net cash position of $371.47 million or $4.37 per share.
| Cash & Cash Equivalents | 372.78M |
| Total Debt | 1.31M |
| Net Cash | 371.47M |
| Net Cash Per Share | $4.37 |
| Equity (Book Value) | 364.47M |
| Book Value Per Share | 4.29 |
| Working Capital | 365.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$74.75 million and capital expenditures -$86,000, giving a free cash flow of -$74.83 million.
| Operating Cash Flow | -74.75M |
| Capital Expenditures | -86,000 |
| Free Cash Flow | -74.83M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |